The latest data point for PFE's EV/Sales ratio in Q1'26 stands at 15.28, reflecting a moderate rebound from the previous quarter's low of 12.40 in Q4'25 and indicating potential stabilization in valuation multiples amid ongoing market dynamics. Over the period from Q2'23 to Q1'26, the EV/Sales ratio exhibited a general downward trend, declining from a peak of 20.82 in Q2'23 to a trough of 11.89 in Q4'24, before showing signs of recovery with fluctuations between 11.92 and 15.28 in the most recent quarters. This volatility suggests sensitivity to sector-specific factors, such as pharmaceutical pricing pressures or revenue growth expectations, with the area chart highlighting a contraction in multiples that could imply improving affordability for investors despite the overall decline. Key inflection points include a sharp drop in Q3'24 to 12.65, underscoring periods of heightened uncertainty.